Artificial intelligence is transforming breast cancer screening by uncovering novel mammographic features linked to risk, paving the way for more precise prevention and risk-reducing strategies.

It is well known that women with higher mammographic density, relative to their age and body mass index, are more likely to develop breast cancer. In addition, increased density can make breast ...

As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment.

The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has reached its enrollment goal of 108,508 women, as announced today by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). The study ...